Following the acquisition of Paige in 2025, Tempus launches its new AI-powered, biomarker prediction solution for digital ...

BIOMAKERS, a precision medicine and oncology intelligence company headquartered in San Francisco, today announced the closing of an additional $8 million. The financing marks a key inflection point as ...

Accurate risk stratification and treatment selection remain central challenges in cancer care. Rapid advances in medical imaging, digital pathology, and ...

The promise of the new agents is to solve the fragmentation problem that plagues finance departments. Unlike a sales leader ...

Deep-learning analysis of routine H&E slides accurately predicts key NSCLC driver mutations, supporting treatment in lung cancer care.

ICE agents now wield a Palantir-built tool that maps out deportation targets like a digital dragnet, pinpointing addresses ...

Objectives Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive arthritis development. Persistent DNA damage in tissues is known to drive a ...